Simmaron Partners with AgelessRx to Advance Groundbreaking Low-Dose Rapamycin Trial for ME/CFS, Long-COVID, and IACCs
Incline Village, NV — Simmaron Research Inc., a 501(c)(3) not-for-profit research foundation, is pleased to announce a strategic partnership with AgelessRx, a leader in decentralized clinical trial execution and telehealth innovation. This collaboration supports Simmaron’s ongoing study titled “Low-Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection-Associated Chronic Conditions” (NCT06257420). Our treatment study hypothesizes that mTOR inhibition through rapamycin may address our observed findings of autophagy impairment and symptoms in a subset of patients with ME/CFS and these Infection-associated Chronic Conditions.
AgelessRx brings a wealth of expertise in executing decentralized, multi-phase clinical trials across diverse therapeutic areas, including geroprotection. Notable accomplishments include their successful double-blinded, randomized, placebo-controlled PEARL Trial on rapamycin’s safety and efficacy in improving healthspan metrics (Results of the PEARL Study).
Key Partnership Benefits:
Uniform Treatment Access: Through their established relationships with leading pharmaceutical manufacturers, AgelessRx will provide patients in Simmaron’s trial with a uniform, compounded generic formulation of low-dose rapamycin.
Clinical Services: AgelessRx will offer centralized clinical support, including safety lab testing and monitoring, ensuring seamless access to trial services for patients nationwide.
Decentralized Trial Expertise: By leveraging their industry-leading platform, AgelessRx enhances Simmaron’s ability to recruit and serve patients in a decentralized, patient-centered manner.
Phase I of Simmaron’s groundbreaking trial, which began just eight months ago, has completed enrollment. Initial results are anticipated in early 2025. These findings will guide enrollment criteria, dose optimization, and Simmaron’s upcoming controlled trial of low-dose rapamycin in ME/CFS and related IACCs.
Advancing the Science of ME/CFS and Long-COVID
“We’ve made incredible progress over the past 8 months,” said Dr. Gunnar Gottschalk, CEO and Lead Principal Investigator of Simmaron Research. “Our partnership with AgelessRx will enable us to refine target dosing, expand patient access, and deliver the required clinical services to enrollees suffering from ME/CFS, Long-COVID, and other Infection-Associated Chronic Conditions. The molecular insights we’ve gathered, particularly regarding mTOR-mediated autophagy impairment, will drive the design and execution of our next trial phase.”
This partnership underscores Simmaron’s commitment to equitably advancing treatment solutions for chronic illnesses that currently lack effective treatments.
Learn More
For more information about Simmaron’s rapamycin trial, visit www.simmaron.com.
To learn about AgelessRx and their innovative telehealth solutions, visit www.agelessrx.com.